(Q44021381)

29 November 2017

Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs (English)

1 reference

29 November 2017

J A Witjes

1

1 reference

29 November 2017

J L J Vriesema

2

1 reference

29 November 2017

A G van der Heijden

3

1 reference

29 November 2017

G J Peters

4

1 reference

29 November 2017

J A Schalken

5

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

29 November 2017

1 reference

29 November 2017

44

1 reference

29 November 2017

615-619

1 reference

29 November 2017

5

1 reference

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Bacille Calmette-Guérin in superficial transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Surgically induced urologic models in swine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Concentration of nucleotides and deoxynucleotides in peripheral and phytohemagglutinin-stimulated mammalian lymphocytes. Effects of adenosine and deoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900372-5

7 January 2021

10.1016/S0302-2838(03)00372-5

Identifiers

DOI

1 reference

29 November 2017

1 reference